Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.
Le Caer H, Borget I, Corre R, Locher C, Raynaud C, Decroisette C, Berard H, Audigier-Valette C, Dujon C, Auliac JB, Crequit J, Monnet I, Vergnenegre A, Chouaid C. Le Caer H, et al. Among authors: crequit j. J Thorac Dis. 2017 Oct;9(10):3747-3754. doi: 10.21037/jtd.2017.09.51. J Thorac Dis. 2017. PMID: 29268382 Free PMC article.
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Chouaid C, Le Caer H, Corre R, Crequit J, Locher C, Falchero L, Dujon C, Berard H, Monnet I, Vergnenegre A. Chouaid C, et al. Among authors: crequit j. Clin Lung Cancer. 2013 Mar;14(2):103-7. doi: 10.1016/j.cllc.2012.04.006. Epub 2012 Jun 7. Clin Lung Cancer. 2013. PMID: 22682669 Clinical Trial.
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study).
LeCaer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, Vergnenegre A, Dujon C, Delhoume JY, Chouaid C; GFPC 0504 Team. LeCaer H, et al. Br J Cancer. 2011 Oct 11;105(8):1123-30. doi: 10.1038/bjc.2011.331. Epub 2011 Sep 20. Br J Cancer. 2011. PMID: 21934690 Free PMC article. Clinical Trial.
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study).
LeCaer H, Greillier L, Corre R, Jullian H, Crequit J, Falchero L, Dujon C, Berard H, Vergnenegre A, Chouaid C; GFPC 0505 Team. LeCaer H, et al. Among authors: crequit j. Lung Cancer. 2012 Jul;77(1):97-103. doi: 10.1016/j.lungcan.2012.02.004. Epub 2012 Mar 8. Lung Cancer. 2012. PMID: 22405570 Clinical Trial.
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C; GFPC 08–2015 ENERGY investigators. Léna H, et al. Lancet Respir Med. 2024 Oct 29:S2213-2600(24)00264-9. doi: 10.1016/S2213-2600(24)00264-9. Online ahead of print. Lancet Respir Med. 2024. PMID: 39486424
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.
Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N, Morel H, Duval Y, Asselain B, Letierce A, Trédaniel J, Auliac JB, Bylicki O, Moreau L, Fore M, Corre R, Couraud S, Cortot A; Study Group KBP-2020-CPHG; KBP-2020-CPHG. Debieuvre D, et al. Lancet Reg Health Eur. 2022 Aug 29;22:100492. doi: 10.1016/j.lanepe.2022.100492. eCollection 2022 Nov. Lancet Reg Health Eur. 2022. PMID: 36108315 Free PMC article.
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Peters S, et al. Among authors: crequit j. Lung Cancer. 2021 Nov;161:76-85. doi: 10.1016/j.lungcan.2021.09.002. Epub 2021 Sep 9. Lung Cancer. 2021. PMID: 34543941 Free article. Clinical Trial.
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C; Groupe Français de Pneumo-Cancérologie 01–13 investigators. Baize N, et al. Among authors: crequit j. Lancet Oncol. 2020 Sep;21(9):1224-1233. doi: 10.1016/S1470-2045(20)30461-7. Lancet Oncol. 2020. PMID: 32888454 Clinical Trial.
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01).
Vergnenègre A, Basse V, Le Garff G, Bylicki O, Dubos-Arvis C, Comet B, Marcq M, Le Treut J, Auliac JB, Madroszyk A, Fraboulet G, Crequit J, Thomas P, Paleiron N, Monnet I; French Lung Cancer Group. Vergnenègre A, et al. Among authors: crequit j. Cancer Manag Res. 2019 Dec 27;11:10821-10826. doi: 10.2147/CMAR.S219984. eCollection 2019. Cancer Manag Res. 2019. PMID: 31920391 Free PMC article.
24 results